Navigation Links
Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
Date:1/31/2012

DURHAM, N.C., Jan. 31, 2012 /PRNewswire/ -- Argos Therapeutics Inc., today announced that it presented a high resolution immune monitoring analysis of AGS-003-006, a Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with advanced renal cell carcinoma (RCC). The results showed a statistically significant correlation between anti-tumor memory T cell responses and overall survival. AGS-003 in combination with sunitinib overcame the immuno-suppressive environment of RCC and induced a tumor-specific multi-functional memory CTL response. The results were presented orally at the Global Technology Community's (GTC) 4th Immunotherapeutics and Immunomonitoring Conference in San Diego.

"We believe that the high resolution immune monitoring analysis of the Phase 2 study of AGS-003 and sunitinib represents the first time that pattern recognition algorithms originally developed for gene microarray datasets have been applied to an immunologic dataset to identify immune correlates to clinical outcome," said Charles Nicolette, Ph.D., Argos' chief scientific officer and vice president of research and development. "The multiparametric flow cytometry data from the study that we analyzed demonstrated that the combination of AGS-003 and sunitinib induced tumor-specific multi-functional memory CTL that were statistically significant correlates to overall survival in the study, thereby supporting the intended mechanism of action of AGS-003."

AGS-003-006 was an open label Phase 2 trial of AGS-003 in combination with sunitinib in patients with newly diagnosed, unfavorable-risk, metastatic clear cell RCC. AGS-003 was designed to stimulate the proliferation and multi-functionality of CTLs targeted directly to the autologous RCC tumor antigens.  In analyzing the data from the trial we sought to detect immune correlates by using multi-parametric flow cytometry to identify 16 unique RCC antigen reactive CTL subsets ba
'/>"/>

SOURCE Argos Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
2. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
3. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
5. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
7. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Silence Therapeutics Additional Listing
10. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
11. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015  InCarda Therapeutics, Inc. (InCarda), ... and commercialization of therapies for acute cardiovascular conditions ... of a Series A financing. In this financing, ... totaling an additional $1.5 million. The lead investor ... include a consortium of physicians and other health ...
(Date:4/28/2015)... Mich. , April 28, 2015 Data ... today shows that the Paradigm Cancer Diagnostic Test ... a number of key clinical variables, including turnaround time ... purpose of the analysis was to interrogate and assess ... patients compared with each other.  In ...
(Date:4/28/2015)... 28, 2015 IMS is releasing ... it to the web and provide greater accessibility ... friendly reporting metrics increase data warehouse’s utility; plus, ... recall and access “on-the-go” makes data analysis even ... client feedback to assist in repository analytics and ...
(Date:4/28/2015)... Reproductive endocrinologist Dr. Kaylen Silverberg , on ... infertility in this country, testified on behalf of House ... state in the nation to consider creating a clearinghouse to ... desire to receive them. , Infertility affects over 7.3 million ... one of the few medical diseases that is curable, the ...
Breaking Biology Technology:InCarda Therapeutics Completes Over $5 Million Private Financing 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3
... (Nasdaq: GPRO ) announced today that it ... of credit to finance its pending acquisition of Tepnel ... its existing share repurchase program.The Company will pay interest ... by Bank of America, at a floating rate 0.6 ...
... As Part of "In the Zone for UC" Campaign, ... Crohn,s & Colitis Foundation of America for Each Point ... Centocor Ortho Biotech Inc. announced today a partnership ... of ulcerative colitis (UC) and funding to support continued ...
... to resume manufacturing at KV facilitiesST. LOUIS, March 2 ... it has entered into a consent decree with the ... drug manufacturing and distribution. The decree provides a ... to resume the manufacture and distribution of products marketed ...
Cached Biology Technology:Gen-Probe Borrows $170 Million Under New Line of Credit 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4KV Pharmaceutical Enters Into Consent Decree With FDA 2KV Pharmaceutical Enters Into Consent Decree With FDA 3KV Pharmaceutical Enters Into Consent Decree With FDA 4KV Pharmaceutical Enters Into Consent Decree With FDA 5KV Pharmaceutical Enters Into Consent Decree With FDA 6
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... An international team of scientists has published a new ... extinct, natural habitats become less productive and contain fewer total ... that humans get from nature. The article ... of the National Academy of Sciences the week of Nov. ...
... in an expanded access program for sapropterin dihydrochloride, ... a rare genetic metabolic disorder that, if left ... severe mental retardation. Currently, there are eight patients ... Childrens. Under an expanded access program, the ...
... Children who possess a gene known to increase the ... cognitive function, an Oregon Health & Science University study ... of Medicine discovered that 7- to 10-year-olds with a ... nerve cell regeneration and neuroprotection display reduced spatial learning ...
Cached Biology News:Scientists warn that species extinction could reduce productivity of plants on Earth by half 2Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2Children with gene show reduced cognitive function 2
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... separation system using the asymmetric flow Field ... easily with Wyatts multi-angle light scattering (MALS) ... the Optilab DSP. The combined system provides ... the particles/molecules separated by the AFFF unit. ...
... reagent kit for determining the absolute count ... samples, mobilized peripheral blood samples, and leukapheresis ... total nucleated cell count and a total ... designed for use in the BD Procount ...
... poorly to Protein A and, until recently, no ... step IgM purification. Standard methods for IgM purification ... not effective for removing all of the major ... Pierce has developed an easy-to-use affinity ...
Biology Products: